FOLLOWING the Therapeutic
Goods Administration’s approval
of the drug (PD 29 Jul), MSD’s
etanercept biosimilar Brenzys
(originator brand Enbrel from
Pfizer) has been recommended for
Pharmaceutical Benefit Scheme
funding by the Pharmaceutical
Benefits Advisory Committee
(PBAC) in their July meeting.
The product is endorsed for
rheumatoid arthritis, psoriatic
arthritis, plaque psoriasis and
ankylosing spondylitis and is ‘a’
flagged for pharmacist substitution.
The PBAC noted that the
pharmacist substitution process for
the medication allows for patient
and prescriber choice.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Aug 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.